Core Viewpoint - The passing of Sun Yan, a pioneer in clinical oncology in China, marks a significant loss for the field, as he was instrumental in establishing and advancing oncology treatment and research in the country [1][2]. Group 1: Contributions to Oncology - Sun Yan was a founding figure in China's oncology field, advocating for comprehensive treatment approaches and leading the development of over 30 new drugs, including the first small-molecule targeted cancer drug with complete independent intellectual property rights in China, Alectinib [1][2]. - He initiated nearly 80 clinical trials and trained over a thousand oncology professionals, significantly contributing to the growth of oncology as a discipline in China [1][2]. - His efforts in drug development and clinical research not only advanced medical science but also positively impacted local economies, exemplified by his role in alleviating poverty in the Dingxi region through the promotion of local pharmaceutical products [1]. Group 2: Legacy and Recognition - Sun Yan's legacy includes the establishment of the Chinese Society of Clinical Oncology (CSCO), which he helped to found, promoting collaboration and communication with international organizations [2]. - He received numerous accolades, including the National Science and Technology Progress Award and the title of Advanced Worker in the National Health System, reflecting his significant contributions to the field [3]. - His dedication to education and mentorship has left a lasting impact, with many professionals in the oncology field crediting him for their foundational training and guidance [3].